Key result
High baseline HOMA-IR was an independent predictor for new onset type 2 diabetes in non-diabetic adults younger than 65 years.
Cohort (n=4,314)
Answers are grounded in this paper and cite their sources.
BACKGROUND: Homeostasis model assessment for insulin resistance (HOMA-IR) is a biomarker for type 2 diabetes mellitus (T2DM). However, the role of HOMA-IR in the non-diabetic is unclear. This study aimed to determine whether IR measured HOMA-IR value is associated with new onset diabetes as well as vascular disease and can be used as an early predictor for diabetes and vascular diseases in non-diabetic participants. METHODS: From a prospective community-based cohort of 10,030 individuals, 4314 individuals younger than 65 years and without diabetes were enrolled and divided into three groups by baseline HOMA-IR tertiles: low (n = 1454), moderate (n = 1414), and high (n = 1446). The primary outcome was new onset T2DM. Secondary outcomes were chronic kidney disease (CKD) and a composite of coronary artery disease, myocardial infarction, and stroke as macrovascular events. RESULTS: The mean age was 51 years. The prevalence of hypertension and cholesterol and HbA1c were higher in the high HOMA-IR group. New onset T2DM (5.8%) and CKD (12.2%) incidence in the high HOMA-IR group was higher than that in the others. The prevalence of macrovascular events did not differ among groups. High-HOMA-IR was an independent risk factor for new onset T2DM (odds ratio 1.86 [1.17-2.96]; p = 0.01) and CKD (1.49 [1.12-1.98]; p = 0.01). CONCLUSIONS: High HOMA-IR was an early predictor of new onset T2DM and CKD, regardless of HbA1c in non-diabetic individuals. Further research on the specific cut off value will be needed.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) conducted a cohort in Non-diabetic (n=4,314). High HOMA-IR vs. Low and moderate HOMA-IR was evaluated on new onset T2DM (OR 1.86, 95% CI 1.17-2.96, p=0.01). High baseline HOMA-IR was an independent predictor for new onset type 2 diabetes in non-diabetic adults younger than 65 years.
Synapse has enriched 10 related papers. Consider them for comparative context: